Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Quercis Pharma.

    Client Virtual Booth

    QUERCIS PHARMA

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Quercis Pharma
    Switzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Nordstrass 5 6300 Zug
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.quercis.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/quercis-pharma/
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Western New England University and Quercis Pharma Sign Exclusive Worldwide License Agreements

    Details:

    Zafirlukast (Accolate®) is in a class of medications known as leukotriene receptor antagonists (LTRAs) that work by blocking the action of certain natural substances that cause swelling and tightening of the airways.


    Lead Product(s): Zafirlukast

    Therapeutic Area: Hematology Product Name: Undisclosed

    Highest Development Status: Phase IIProduct Type: Small molecule

    Recipient: Western New England University

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement May 19, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Quercis Announces Special Protocol Assessment Agreement with U.S. Food and Drug Administration

    Details:

    SPA supports protocol for Phase 3 Trial of Isoquercetin to effect thromboembolic events in metastatic pancreatic cancer patients. Isoquercetin employs a novel pathway that is based on a new mechanism of action to prevent or reverse thrombus formation.


    Lead Product(s): Isoquercitrin

    Therapeutic Area: Cardiology/Vascular Diseases Product Name: ISQ950AN

    Highest Development Status: Phase IIIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: FDA

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement May 04, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search